Leishmaniasis treatment: update of possibilities for drug repurposing

VV Andrade Neto, EF Cunha Junior, VS Faioes… - 2018 - arca.fiocruz.br
The leishmaniases represent a public health problem in under-developed countries and are
considered a neglected disease by the World Health Organization (WHO). They are cuased …

Leishmanicidal Activity of Piper nigrum Bioactive Fractions is Interceded via Apoptosis In Vitro and Substantiated by Th1 Immunostimulatory Potential In Vivo

G Chouhan, M Islamuddin, MY Want… - Frontiers in …, 2015 - frontiersin.org
Visceral leishmaniasis (VL) is a life-threatening protozoal infection chiefly impinging the
rural and poor population in the tropical and sub-tropical countries. The deadly affliction is …

[PDF][PDF] Bibliography of scientific publications on vector-borne diseases from WHO South-East Asia region 2009-2013

World Health Organization - 2014 - apps.who.int
Vector-borne diseases account for 17% of the estimated global burden of all infectious
diseases. While malaria is still the deadliest vector-borne disease, dengue has become the …

[HTML][HTML] In-vitro and in-vivo antileishmanial activity of a compound derived of platinum, oxaliplatin, against Leishmania major

E Ghasemi, F Ghaffarifar, A Dalimi… - Iranian journal of …, 2019 - ncbi.nlm.nih.gov
This study aimed to evaluate the antileishmanial efficacy of oxaliplatin against Leishmania
major (L. major) both in-vitro and in-vivo. The IC 50, CC 50, and SI of oxaliplatin against …

Target-Based Rational Improvement Strategies and Pitfalls in Leishmania Drug Discovery

Y Gupta, S Goicoechea, J Vance, AP Trujillo… - Natural Product Based …, 2023 - Springer
Worldwide parasite infection, especially Leishmania, is the most severe high morbidity and
mortality issue. It is one of the leading protozoans parasitic agents responsible for causing …